Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis : Two Nationwide Cohort Studies

• Published in: Annals of internal medicine Vol. 174; no. 6; p. 737
• Main Authors: Gaber, Charles E, Kinlaw, Alan C, Edwards, Jessie K, Lund, Jennifer L, Stürmer, Til, Peacock Hinton, Sharon, Pate, Virginia, Bartelt, Luther A, Sandler, Robert S, Peery, Anne F
• Format: Journal Article
• Language: English
• Published: United States 01.06.2021
• Subjects: Adolescent; Adult; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination - adverse effects; Amoxicillin-Potassium Clavulanate Combination - therapeutic use; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Clostridium Infections - diagnosis; Comparative Effectiveness Research; Cost of Illness; Diverticulitis - drug therapy; Diverticulitis - surgery; Female; Fluoroquinolones - adverse effects; Fluoroquinolones - therapeutic use; Hospitalization; Humans; Male; Metronidazole - adverse effects; Metronidazole - therapeutic use; Middle Aged; Retrospective Studies; Risk Factors; Young Adult
• ISSN: 1539-3704
• DOI: 10.7326/M20-6315

Outpatient diverticulitis is commonly treated with either a combination of metronidazole and a fluoroquinolone (metronidazole-with-fluoroquinolone) or amoxicillin-clavulanate alone. The U.S. Food and Drug Administration advised that fluoroquinolones be reserved for conditions with no alternative treatment options. The comparative effectiveness of metronidazole-with-fluoroquinolone versus amoxicillin-clavulanate for diverticulitis is uncertain. To determine the effectiveness and harms of metronidazole-with-fluoroquinolone versus amoxicillin-clavulanate for outpatient diverticulitis. Active-comparator, new-user, retrospective cohort studies. Nationwide population-based claims data on U.S. residents aged 18 to 64 years with private employer-sponsored insurance (2000 to 2018) or those aged 65 years or older with Medicare (2006 to 2015). Immunocompetent adults with diverticulitis in the outpatient setting. Metronidazole-with-fluoroquinolone or amoxicillin-clavulanate. 1-year risks for inpatient admission, urgent surgery, and infection (CDI) and 3-year risk for elective surgery. In MarketScan (IBM Watson Health), new users of metronidazole-with-fluoroquinolone ( = 106 361) and amoxicillin-clavulanate ( = 13 160) were identified. There were no differences in 1-year admission risk (risk difference, 0.1 percentage points [95% CI, -0.3 to 0.6]), 1-year urgent surgery risk (risk difference, 0.0 percentage points [CI, -0.1 to 0.1]), 3-year elective surgery risk (risk difference, 0.2 percentage points [CI, -0.3 to 0.7]), or 1-year CDI risk (risk difference, 0.0 percentage points [CI, -0.1 to 0.1]) between groups. In Medicare, new users of metronidazole-with-fluoroquinolone ( = 17 639) and amoxicillin-clavulanate ( = 2709) were identified. There were no differences in 1-year admission risk (risk difference, 0.1 percentage points [CI, -0.7 to 0.9]), 1-year urgent surgery risk (risk difference, -0.2 percentage points [CI, -0.6 to 0.1]), or 3-year elective surgery risk (risk difference, -0.3 percentage points [CI, -1.1 to 0.4]) between groups. The 1-year CDI risk was higher for metronidazole-with-fluoroquinolone than for amoxicillin-clavulanate (risk difference, 0.6 percentage points [CI, 0.2 to 1.0]). Residual confounding is possible, and not all harms associated with these antibiotics, most notably drug-induced liver injury, could be assessed. Treating diverticulitis in the outpatient setting with amoxicillin-clavulanate may reduce the risk for fluoroquinolone-related harms without adversely affecting diverticulitis-specific outcomes. National Institutes of Health.